# FCPM III SERVICES B.V.: Form 13F holdings

An institutional investment manager in NAARDEN. SEC CIK 2013410.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $750.4m
- Positions: 11 (15 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/2013410/000119312526350207/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | $287.7m | 38.3% | 8,490,353 |  | Reduced −708,547 |
| [MAPLIGHT THERAPEUTICS INC (MPLT)](/companies/mplt.md) | COM | $115.6m | 15.4% | 3,226,400 |  | Unchanged |
| [DYNE THERAPEUTICS INC (DYN)](/companies/dyn.md) | COM | $85.5m | 11.4% | 3,848,256 |  | Reduced −796,130 |
| [VOR BIOPHARMA INC (VOR)](/companies/vor.md) | COM NEW | $75.8m | 10.1% | 4,117,354 |  | Unchanged |
| DAMORA THERAPEUTICS INC | COM NEW | $63.5m | 8.5% | 2,441,000 |  | Unchanged |
| [REPLIMUNE GROUP INC (REPL)](/companies/repl.md) | COM | $31.1m | 4.1% | 2,808,368 |  | Unchanged |
| CRESCENT BIOPHARMA INC. | COM | $30.2m | 4.0% | 1,677,852 |  | Unchanged |
| [AURA BIOSCIENCES INC (AURA)](/companies/aura.md) | COM | $28.8m | 3.8% | 4,053,775 |  | New +4,053,775 |
| ENGENE HOLDINGS INC | COM | $16.7m | 2.2% | 9,632,561 |  | Unchanged |
| [BICYCLE THERAPEUTICS PLC (BCYC)](/companies/bcyc.md) | SPONSORED ADS | $14.7m | 2.0% | 3,468,430 |  | Unchanged |
| ENGENE HOLDINGS INC | W EXP  10/31/2028 | $834.4k | 0.1% | 2,878,148 |  | Unchanged |

Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-350207. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.